Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit

Desriani, Budiarto BR, Harahap WA, Warisman MA,Ompusunggu AVC, Athariah D, Mirnawati F, Sriyani IY, Alahwani F, Kurniawan AR. 2016. Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit. Biodivers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	DESRIANI DESRIANI, BUGI RATNO BUDIARTO, WIRSMA ARIF HARAHAP, M. ALI WARISMAN, AUDREY VANIA CLARISSA OMPUSUNGGU, DINA ATHARIAH, FARIDA MIRNAWATI, IDA YUSSRIYANI, FUAD ALAHWANI, AHMAD RIZQI KURNIAWAN
Formato:	article
Lenguaje:	EN
Publicado:	MBI & UNS Solo 2016
Materias:	breast cancer, dna, pik3ca, her-2, resistance trastuzumab, mutation Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/29ca8fefc9614933ad16716e51e23f79
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29ca8fefc9614933ad16716e51e23f79
record_format	dspace
spelling	oai:doaj.org-article:29ca8fefc9614933ad16716e51e23f792021-11-14T02:27:09ZData provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit1412-033X2085-472210.13057/biodiv/d170237https://doaj.org/article/29ca8fefc9614933ad16716e51e23f792016-08-01T00:00:00Zhttps://smujo.id/biodiv/article/view/340https://doaj.org/toc/1412-033Xhttps://doaj.org/toc/2085-4722Desriani, Budiarto BR, Harahap WA, Warisman MA,Ompusunggu AVC, Athariah D, Mirnawati F, Sriyani IY, Alahwani F, Kurniawan AR. 2016. Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit. Biodiversitas 17: 647-652. HER-2 overexpression is well known as a poor prognostic factor for breast cancer patients. Targeted therapy can be carried out using monoclonal antibody named trastuzumab. Some reports have higlighted the core problem of HER2 positive-breast cancer resitance on trastuzumab due to incorrect in selecting HER2 status patient who will reciept the drug and the emergence of PIK3CA mutations especially in exon 9 and 20 which is the downstream of HER-2 pathway. In this study, data provision of PIK3CA gene and preparation of plasmid to support developing the trastuzumab predictive response diagnostic kits will be reported. Based on direct DNA sequencing result, two samples of 68 breast cancer patients exhibited mutation at exon 20 H1047R, while another three samples showed silent mutation (T1025T) at the same exon. On the other hand, careful strategy should be considered for exon 9 analysis, since we found that almost 68 samples sequenced none of them were exon 9 positive (pesudogene). Two prepared plasmids, pGEMT-easy PIK3CA exon 9 and 20 will be applied as control PIK3CA gene for qPCR SYBR green I-based PIK3CA genotyping, while pGEMT easy HER-2 will be applied as a reference gene for scoring HER-2 status. The standard curve equation of plasmid-cloned HER2 gene amplification was Y=-3,0472x + 46,465, R2= 0,99 with qPCR efficiency was 115%, respectively. Inconclusion, data provision and control DNA preparation of predicted factors for breast cancer patients who positively respond to trastuzumab are very fundamental important aspects for the development of trastuzumab response diagnostic kit which is based on Indonesian population genetics profile.DESRIANI DESRIANIBUGI RATNO BUDIARTOWIRSMA ARIF HARAHAPM. ALI WARISMANAUDREY VANIA CLARISSA OMPUSUNGGUDINA ATHARIAHFARIDA MIRNAWATIIDA YUSSRIYANIFUAD ALAHWANIAHMAD RIZQI KURNIAWANMBI & UNS Soloarticlebreast cancer, dna, pik3ca, her-2, resistance trastuzumab, mutationBiology (General)QH301-705.5ENBiodiversitas, Vol 17, Iss 2 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer, dna, pik3ca, her-2, resistance trastuzumab, mutation Biology (General) QH301-705.5
spellingShingle	breast cancer, dna, pik3ca, her-2, resistance trastuzumab, mutation Biology (General) QH301-705.5 DESRIANI DESRIANI BUGI RATNO BUDIARTO WIRSMA ARIF HARAHAP M. ALI WARISMAN AUDREY VANIA CLARISSA OMPUSUNGGU DINA ATHARIAH FARIDA MIRNAWATI IDA YUSSRIYANI FUAD ALAHWANI AHMAD RIZQI KURNIAWAN Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
description	Desriani, Budiarto BR, Harahap WA, Warisman MA,Ompusunggu AVC, Athariah D, Mirnawati F, Sriyani IY, Alahwani F, Kurniawan AR. 2016. Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit. Biodiversitas 17: 647-652. HER-2 overexpression is well known as a poor prognostic factor for breast cancer patients. Targeted therapy can be carried out using monoclonal antibody named trastuzumab. Some reports have higlighted the core problem of HER2 positive-breast cancer resitance on trastuzumab due to incorrect in selecting HER2 status patient who will reciept the drug and the emergence of PIK3CA mutations especially in exon 9 and 20 which is the downstream of HER-2 pathway. In this study, data provision of PIK3CA gene and preparation of plasmid to support developing the trastuzumab predictive response diagnostic kits will be reported. Based on direct DNA sequencing result, two samples of 68 breast cancer patients exhibited mutation at exon 20 H1047R, while another three samples showed silent mutation (T1025T) at the same exon. On the other hand, careful strategy should be considered for exon 9 analysis, since we found that almost 68 samples sequenced none of them were exon 9 positive (pesudogene). Two prepared plasmids, pGEMT-easy PIK3CA exon 9 and 20 will be applied as control PIK3CA gene for qPCR SYBR green I-based PIK3CA genotyping, while pGEMT easy HER-2 will be applied as a reference gene for scoring HER-2 status. The standard curve equation of plasmid-cloned HER2 gene amplification was Y=-3,0472x + 46,465, R2= 0,99 with qPCR efficiency was 115%, respectively. Inconclusion, data provision and control DNA preparation of predicted factors for breast cancer patients who positively respond to trastuzumab are very fundamental important aspects for the development of trastuzumab response diagnostic kit which is based on Indonesian population genetics profile.
format	article
author	DESRIANI DESRIANI BUGI RATNO BUDIARTO WIRSMA ARIF HARAHAP M. ALI WARISMAN AUDREY VANIA CLARISSA OMPUSUNGGU DINA ATHARIAH FARIDA MIRNAWATI IDA YUSSRIYANI FUAD ALAHWANI AHMAD RIZQI KURNIAWAN
author_facet	DESRIANI DESRIANI BUGI RATNO BUDIARTO WIRSMA ARIF HARAHAP M. ALI WARISMAN AUDREY VANIA CLARISSA OMPUSUNGGU DINA ATHARIAH FARIDA MIRNAWATI IDA YUSSRIYANI FUAD ALAHWANI AHMAD RIZQI KURNIAWAN
author_sort	DESRIANI DESRIANI
title	Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
title_short	Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
title_full	Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
title_fullStr	Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
title_full_unstemmed	Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
title_sort	data provision of pik3ca gene diversity and recombinant plasmids preparation for control dna in developing the trastuzumab predictive response diagnostic kit
publisher	MBI & UNS Solo
publishDate	2016
url	https://doaj.org/article/29ca8fefc9614933ad16716e51e23f79
work_keys_str_mv	AT desrianidesriani dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT bugiratnobudiarto dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT wirsmaarifharahap dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT maliwarisman dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT audreyvaniaclarissaompusunggu dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT dinaathariah dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT faridamirnawati dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT idayussriyani dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT fuadalahwani dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit AT ahmadrizqikurniawan dataprovisionofpik3cagenediversityandrecombinantplasmidspreparationforcontroldnaindevelopingthetrastuzumabpredictiveresponsediagnostickit
_version_	1718430064684564480

Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit

Ejemplares similares